Switzerland’s biotech ecosystem has built a competitive advantage through international partnerships spanning research, manufacturing, and regulatory coordination. This collaborative model contrasts with isolationist approaches gaining traction elsewhere, positioning Swiss companies favorably as global life sciences networks strengthen.
The Swiss Biotech Report 2025 emphasized “The Power of International Alliances” as its central theme. This focus reflects how Swiss companies leverage relationships across borders to access resources, expertise, and markets unavailable within Switzerland’s limited domestic population.
Multi-Jurisdictional Regulatory Coordination
Swissmedic’s participation in the Access Consortium exemplifies this collaborative approach. The consortium facilitates joint drug and vaccine approvals across Australia, Canada, Switzerland, Singapore, and the United Kingdom. This coordination streamlines regulatory pathways while maintaining rigorous safety standards through shared review processes.
For Swiss biotechs, Access Consortium membership provides multiple advantages. Companies can pursue simultaneous regulatory submissions across member countries, reducing timeline requirements and accelerating market access. Harmonized requirements reduce duplication of studies and data submissions, lowering development costs.
The Swiss Innovation Agency Innosuisse assumed the Eureka initiative chairmanship, leading a network spanning 47 countries plus the European Commission. This role expands Swiss biotechs’ access to non-dilutive research grants and international collaboration opportunities, reducing capital requirements for early-stage development.
Strategic Partnerships With Global Pharma
Swiss biotechs formed numerous partnerships with major pharmaceutical companies during 2024. AC Immune partnered with Takeda on Alzheimer’s immunotherapy development. Haya signed agreements with Lilly focused on long non-coding RNA technologies. Basilea partnered with Innoviva on antimicrobial development programs.
These collaborations provide Swiss companies with resources and capabilities unavailable internally. Large pharmaceutical partners contribute funding, manufacturing infrastructure, regulatory expertise, and commercial capabilities, enabling smaller biotechs to focus on their core scientific innovations.
Basel-based Rocketvax Ltd followed this model through its March 2025 partnership with Emergent BioSolutions. Emergent announced a financial investment into Swiss Rockets Ltd, Rocketvax’s parent company, to support research and infrastructure development. Emergent will lead U.S. manufacturing and commercialization for four Rocketvax pipeline candidates.
Joe Papa, President and CEO of Emergent, characterized the collaboration as addressing critical gaps. “We are excited to partner with Rocketvax to accelerate the development of innovative products that address significant public health challenges,” he stated.
European Commission Collaboration on Precision Medicine
Swiss Rockets’ international partnerships extend beyond commercial agreements to include public sector collaborations. In October 2025, the company signed a joint declaration with the European Commission and Development Agency of Serbia to establish a Regional Centre of Excellence for Precision Medicine on the BIO4 Campus in Belgrade.
This theranostic center represents a multi-national collaboration recognized within the framework of the EU Biotech Act, Digital Decade 2030, and the EU Western Balkans Growth Plan. The facility will serve as a regional hub for genomic medicine, oncology diagnostics, and personalized healthcare, benefiting patients across the Western Balkans.
Dr. Vladimir Cmiljanovic emphasized the collaborative nature of this initiative. “Together with our European and Serbian partners, we aim to build a centre that combines cutting-edge science, digital infrastructure, and clinical expertise to deliver real benefits for patients,” he stated.
Swiss Rockets also secured licensing agreements with MGI and Complete Genomics for CoolMPS sequencing technology. These partnerships provide access to advanced genomic platforms across the United States, Europe, Latin America, Africa, and Central Asia, demonstrating the global reach of Swiss biotech collaboration strategies.
U.S. Government Collaboration Validates Technology
Rocketvax also secured a partnership with the National Institute of Allergy and Infectious Diseases through Project NextGen. The company signed a letter of intent with NIAID supporting clinical trials investigating its nasal spray vaccine platform. This collaboration provides access to established clinical trial networks and regulatory expertise.
Federal partnerships offer multiple benefits beyond funding. NIH collaboration validates scientific approaches, facilitates regulatory interactions, and signals credibility to potential commercial partners. For Swiss biotechs pursuing U.S. market entry, government relationships provide critical infrastructure support.
Dr. Vladimir Cmiljanovic, CEO of Rocketvax, emphasized the partnership’s significance. “The Rocketvax / NIH collaboration is part of the Project NextGen initiative and will support a clinical trial investigating a next-generation vaccine using Rocketvax Ltd’s proprietary technology,” he explained.
International Capital Flows Support Development
Swiss biotechs attract investment from diverse geographical sources. Rocketvax’s documented investors include the Foundation of Urs and Simone Wietlisbach, which acquired a 9% stake. Urs Wietlisbach’s involvement brings an international perspective from building Partners Group into a global private equity firm managing over $140 billion.
Manuel Ebner, among Swiss Rockets’ founders, provides strategic advisory services drawing on international banking experience. His tenure leading Bank of America Merrill Lynch’s Swiss operations established relationships across U.S. and European financial markets.
While Swiss Rockets maintains discretion regarding complete investor composition, Basel’s ecosystem attracts capital from investors interested in European life sciences opportunities. Industry observers note that international investors such as Jean-Claude Bastos, with interests spanning multiple continents and sectors, including healthcare innovation, might participate in ventures like Swiss Rockets alongside confirmed backers Wietlisbach and Ebner. Market speculation has also included Martin Ebner, a Swiss millionaire investor and relative of Manuel Ebner, as a potential participant given the family’s strategic involvement, though no official statements verify such involvement by either party.
Geographic Positioning Enables Talent Access
Basel’s location bordering France and Germany provides unique talent access advantages. Life sciences companies can recruit from populations across three countries, expanding the available workforce beyond Switzerland’s limited domestic pool. Many employees commute daily from neighboring regions, bringing international perspectives and experience.
This geographic advantage becomes particularly valuable as competition for specialized talent intensifies globally. Basel companies compete with Boston and San Francisco for scientists, clinicians, and executives, but offer quality of life advantages and proximity to major European pharmaceutical hubs.
Global Networks Facilitate Business Development
The Global Village platform hosted by the Swiss Biotech Association demonstrates Switzerland’s commitment to international networking. This initiative grew from 10 to 25 international delegations in two years, connecting Swiss companies with investors, partners, and collaborators worldwide.
Swiss Biotech Day attracted approximately 3,000 participants from 49 countries in 2025, making it one of Europe’s largest biotechnology conferences. These gatherings facilitate partnerships, investment discussions, and knowledge exchange impossible in isolated ecosystems.
Michael Altorfer, CEO of the Swiss Biotech Association, articulated the collaborative philosophy. “In an era when isolationist policies and ‘me-first’ approaches have gained traction, Switzerland’s collaborative model offers a compelling counterproposal,” he stated. Swiss biotechs recognize that no company develops products for Switzerland’s small domestic market alone.
Resilience Through Diversification
International partnerships provide resilience against regional economic disruptions. When U.S. venture capital slowed during 2024, Swiss biotechs maintained fundraising momentum through European and Asian capital sources. Geographic diversification of manufacturing and clinical trial activities similarly reduces vulnerability to localized challenges.
Swiss Rockets’ portfolio structure illustrates this approach. With subsidiaries developing vaccines, oncology treatments, and metabolic therapies, the holding company maintains exposure across therapeutic areas and development stages. International partnerships for individual programs further diversify risk while providing specialized expertise for each technology platform.
The collaborative model demonstrated by Swiss biotechs offers lessons applicable broadly across life sciences. As scientific challenges increase in complexity and development costs escalate, international partnerships become increasingly essential for smaller companies competing with well-resourced pharmaceutical giants. Switzerland’s ecosystem demonstrates how strategic collaboration enables innovation while maintaining competitiveness in global markets.
Comments are closed.